Gapping up
In reaction to strong earnings/guidance:
- XRX +5.2%, CIT +4%, GGG +2.6%, AUDC +2.6%, IBTX +2.3%, BRO +2%, LMT +1.9%, SANM +1.7%, ELS +1.6%, PHM +1.4%, WHR +1.1%, AOS +0.8%
M&A news:
- DLPH +60.1% (BorgWarner confirms all-stock acquisition of Delphi; also provided guidance)
Other news:
- XLRN +59.6% (Sotatercept achieves primary and secondary endpoints in Phase 2 trial)
- NH +38.9% (Nant Health and NantOmics presented an AI based machine-learning digital pathology software for lung cancer by identifying tumor infiltrating killer cells from whole slide images)
- CLSD +19.5% (Clearside Biomedical and Bausch Health (BHC) announce that Opthalmology published results from the Phase 3 clinical trial (PEACHTREE study) of XIPERE) SURF +10.3% (FDA clears Investigational New Drug applications for its antibody candidates)
- INCY +4.7% (announces "positive" top-line results from Phase 3 TRuE-AD2 study of ruxolitinib cream)
- ALKS +3.9% (FDA has accepted for review the company's NDA seeking approval of ALKS 3831 for the treatment of schizophrenia and for the treatment of bipolar I disorder
- LAUR +2.3% (to explore strategic alternatives for each of its businesses; reaffirms Q4 guidance)
Analyst comments:
- CGC +4.1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- PCG +1.9% (upgraded to Buy from Neutral at Mizuho)
- WWE +1.3% (initiated with a Buy at Northcoast)
- UBER +1.2% (initiated with a Buy at UBS)